- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No specific kinetic studies have been published in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| CMV infection, adenovirus infection in immunocompromised patients |
|---|
|
| Larynx papillomatosis |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
when the creatinine clearance is 10-50 ml/min: If there are life-threatening indications, using cidofovir combined with probenicid can be considered in consultation with a paediatric nephrologist and hospital pharmacist. An adjusted dose must be individually determined. Consult the available literature: Yusuf 2006 for children; Brody 1999 for adults)
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Significant risk of nephrotoxicity. Cidofovir should only be administered in combination with probenicid and hydration with physiological saline.
Monitoring the renal function and virus concentration is a precondition for being able to evaluate the side effects and the effectiveness. Only administer under well-controlled conditions
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Nucleosides and nucleotides excl. reverse transcriptase inhibitors | ||
|---|---|---|
| J05AB01 | ||
| J05AB06 | ||
| J05AB16 | ||
| J05AB04 | ||
| J05AB11 | ||
| J05AB14 | ||
| Phosphonic acid derivatives | ||
|---|---|---|
| J05AD01 | ||
| Protease inhibitors | ||
|---|---|---|
| J05AE08 | ||
| J05AE10 | ||
| J05AE07 | ||
| J05AE02 | ||
| J05AE04 | ||
| J05AE03 | ||
| J05AE01 | ||
| Nucleoside and nucleotide reverse transcriptase inhibitors | ||
|---|---|---|
| J05AF06 | ||
| J05AF02 | ||
| J05AF09 | ||
| J05AF10 | ||
| J05AF05 | ||
| J05AF04 | ||
| J05AF07 | ||
| J05AF13 | ||
| J05AF13 | ||
| J05AF01 | ||
| Non-nucleoside reverse transcriptase inhibitors | ||
|---|---|---|
| J05AG06 | ||
| J05AG03 | ||
| J05AG04 | ||
| J05AG01 | ||
| J05AG05 | ||
| Neuraminidase inhibitors | ||
|---|---|---|
| J05AH02 | ||
| J05AH01 | ||
| Antivirals for treatment of HIV infections, combinations | ||
|---|---|---|
| J05AR02 | ||
| J05AR20 | ||
| J05AR13 | ||
| J05AR25 | ||
| J05AR18 | ||
| J05AR19 | ||
| J05AR03 | ||
| J05AR09 | ||
| J05AR10 | ||
| Other antivirals | ||
|---|---|---|
| J05AX28 | ||
| J05AX12 | ||
| J05AX07 | ||
| J05AX09 | ||
| J05AX08 | ||
| J05AX24 | ||
| ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS | ||
|---|---|---|
| J05AR02 | ||
| J05AR20 | ||
| J05AR13 | ||
| J05AR25 | ||
| J05AR18 | ||
| J05AR19 | ||
| J05AR03 | ||
| J05AR09 | ||
| J05AR10 | ||
| Integrase inhibitors | ||
|---|---|---|
| J05AJ04 | ||
| Antivirals for treatment of HCV infections | ||
|---|---|---|
| J05AP54 | ||
| J05AP57 | ||
| J05AP51 | ||
| J05AP08 | ||
| J05AP55 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Doan ML, et al, Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients, J Heart Lung Transplant, 2007, Sep;26(9, 883-9
- Chhetri DK, et al, A scheduled protocol for the treatment of juvenile recurrent respiratory papillomatosis with intralesional cidofovir, Arch Otolaryngol Head Neck Surg, 2003, Oct;129(10, 1081-5
- Mandell DL, et al, Intralesional cidofovir for pediatric recurrent respiratory papillomatosis, Arch Otolaryngol Head Neck Surg, 2004, Nov;130(11), 1319-23
- Pransky SM, et al, Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis., Arch Otolaryngol Head Neck Surg, 2000, Oct;126(10), 1239-43
- Pransky SM, et al, Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir., Laryngoscope, 2003, Sep;113(9), 1583-7
- Doan ML, et al, Clinical, radiological and pathological features of ABCA3 mutations in children, Thorax, 2008, Apr;63(4), 366-73
- Anderson EJ, et al, Human intraparietal sulcus (IPS) and competition between exogenous and endogenous saccade plans., tNeuroimage., 2008, Apr 1;40(2):, 838-51
- Legrand F, et al, Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children, Bone Marrow Transplant., 2001, Mar;27(6), 621-6
- Ljungman P, et al, Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation, Blood, 2001, Jan 15;97(2), 388-92
- Yusuf U, et al, Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients, Transplantation, 2006, May 27;81(10), 1398-404
- Anderson EJ, et al, High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy, Pediatr Transplant, 2008, Mar;12(2), 219-27
- Hoffman JA, et al, Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 2001, 7(7), 388-94
- Pransky SM, et al, Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis., Arch Otolaryngol Head Neck Surg, 2000, Oct;126(10), 1239-43
- Legrand F, et al, Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children, Bone Marrow Transplant., 2001, Mar;27(6), 621-6
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
